Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: INT131 besylate is a potent, nonthiazolidinedione, selective peroxisome proliferator–activated receptor γ (PPARγ) modulator (SPPARM) designed to improve glucose metabolism while minimizing the side effects of full PPARγ agonists. This placebo-controlled study compared the efficacy and side effects of INT131 besylate versus 45 mg pioglitazone HCl in subjects with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: This was a 24-week randomized, double-blind, placebo- and active-controlled study of 0.5–3.0 mg INT131 versus 45 mg pioglitazone or placebo daily in 367 subjects with T2D on sulfonylurea or sulfonylurea plus metformin. The primary efficacy analysis was the comparison of change from baseline to week 24 in hemoglobin A1c (HbA1c) across treatment groups. Fluid status was assessed with a prospective scoring system for lower-extremity pitting edema. RESULTS: INT131 had a steep dose response for efficacy as measured by changes in HbA1c. After 24 weeks’ treatment, the 0.5-mg dose demonstrated minimal efficacy (HbA1c −0.3 ± 0.12%) and the 2-mg dose demonstrated near-maximal efficacy (HbA1c −1.1 ± 0.12%), which was not statistically different from the efficacy of 45 mg pioglitazone (HbA1c −0.9 ± 0.12%; P < 0.01 for noninferiority). With the 1-mg dose, INT131 provided significant improvements in glycemic control (HbA1c 0.8 ± 0.12; P < 0.001 vs. placebo) but with less edema, weight gain, and hemodilution than observed with 45 mg pioglitazone. CONCLUSIONS: INT131 demonstrated dose-dependent reductions in HbA1c, equivalent to 45 mg pioglitazone, but with less fluid accumulation and weight gain, consistent with its SPPARM design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
Komajda, M., McMurray, J. J. V., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S. J., Curtis, P. S., Jones, N. P., & Home, P. D. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp604 · Cited by 234
Research works printed but not linked: 20
- Olefsky, 2000, Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists, J Clin Invest, 106, 467, 10.1172/JCI10843 · DOI · Paper page
- Home, 2009, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, Lancet, 373, 2125, 10.1016/S0140-6736(09)60953-3 · DOI · Paper page
- Graham, 2010, Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone, JAMA, 304, 411, 10.1001/jama.2010.920 · DOI · Paper page
- Murphy, 2007, Effects of thiazolidinediones on bone loss and fracture, Ann Pharmacother, 41, 2014, 10.1345/aph.1K286 · DOI · Paper page
- Mudaliar, 2003, Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications, Endocr Pract, 9, 406, 10.4158/EP.9.5.406 · DOI · Paper page
- Nesto, 2004, Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association, Diabetes Care, 27, 256, 10.2337/diacare.27.1.256 · DOI · Paper page
- Lago, 2007, Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials, Lancet, 370, 1129, 10.1016/S0140-6736(07)61514-1 · DOI · Paper page
- Higgins, 2008, The development of INT131 as a selective PPARgamma modulator: approach to a safer insulin sensitizer, PPAR Res, 2008, 936906, 10.1155/2008/936906 · DOI
- Higgins, 2010, Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation, Am J Clin Nutr, 91, 267S, 10.3945/ajcn.2009.28449E · DOI · Paper page
- Motani, 2009, INT131: a selective modulator of PPAR γ, J Mol Biol, 386, 1301, 10.1016/j.jmb.2009.01.025 · DOI
- Lee, 2012, Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice, Am J Physiol Endocrinol Metab, 302, E552, 10.1152/ajpendo.00569.2011 · DOI
- Waites, 2007, Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/γ agonist, Toxicol Sci, 100, 248, 10.1093/toxsci/kfm193 · DOI
- DePaoli, 2008, INT131, a non-TZD selective PPARγ modulator (SPPARM), does not cause toxicities typical of TZD full PPARγ agonists following 6-month high dose treatment of rats or monkeys, Diabetologia, 51, S369
- Dunn, 2011, Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with type 2 diabetes, J Diabetes Complications, 10.1016/j.jdiacomp.2010.06.006 · DOI
- Lebovitz, 2001, Rosiglitazone monotherapy is effective in patients with type 2 diabetes, J Clin Endocrinol Metab, 86, 280, 10.1210/jcem.86.1.7157 · doi:10.1210/jcem.86.1.7157 · Paper page
- Pavo, 2003, Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes, J Clin Endocrinol Metab, 88, 1637, 10.1210/jc.2002-021786 · DOI · Paper page
- Raskin, 2000, Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes, Diabetologia, 43, 278, 10.1007/s001250050045 · DOI · Paper page
- Berger, 2003, Distinct properties and advantages of a novel peroxisome proliferator-activated protein [γ] selective modulator, Mol Endocrinol, 17, 662, 10.1210/me.2002-0217 · DOI · Paper page
- Zhang, 2007, Selective modulators of PPAR-gamma activity: molecular aspects related to obesity and side-effects, PPAR Res, 2007, 32696, 10.1155/2007/32696 · DOI
- Kersey, 2004, T0903131, a selective modulator of PPAR–gamma activity, increases adiponectin levels in healthy subjects (Abstract), Diabetes, 53, A156
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationAdipose tissue in control of metabolism
Luo, L., & Liu, M. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0211 · Cited by 693
Current and future pharmacological therapies for NAFLD/NASH
Sumida, Y., & Yoneda, M. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1415-1 · Cited by 667
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes
Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.005 · Cited by 518
Adiponectin, lipids and atherosclerosis
Katsiki, N., Mantzoros, C., & Mikhailidis, D. P. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000431 · Cited by 170
Self-citation
Metadata
- Authors
- DePaoli, A. M., Higgins, L. S., Henry, R. R., Mantzoros, C., & Dunn, F. L.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-06-12
- Volume
- 37
- Issue
- 7
- Pages
- 1918-1923
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1977484873
- Cited by
- 79
- References
- 3
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone? https://app.cochat.ai/papers/10.2337/dc13-2480
- The paper
- DePaoli, A. M., Higgins, L. S., Henry, R. R., Mantzoros, C., & Dunn, F. L. (2014). Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone? Diabetes Care. https://doi.org/10.2337/dc13-2480
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.